Abstract：Objective: To explore the effect of using Shenmai injection as an adjuvant therapy in patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). Methods: In recent years, 84 ACS patients having undergoing PCI were randomly divided into two groups. The control group was given standardized treatment with western medicine, and the observation group was treated with Shenmai injection. Changes in inflammation, cardiac markers and cardiac function indicators, rates of cardiovascular adverse events and adverse drug reactions were observed. Results:After 2 weeks of treatment, hypersensitive c-reactive protein (hs-crp), endothelin-1 (et-1) and D- were detected in the observation group- D dimer (D) inflammatory indicators, such as superoxide dismutase (SOD), creatine kinase isoenzyme (CK - MB) and troponin -i cardiac markers, such as (cTn - I) levels, and each cardiac output (SV), left ventricular ejection fraction (LVEF), ventricular wall motion index (WMSI) and Seattle angina questionnaire (SAQ) score indicators, improved significantly, compared with the control group (P < 0.05). The rate of adverse cardiovascular events in the observation group was significantly lower than that in the control group (P < 0.05), and there was no difference in the rate of adverse drug reactions between the groups (P > 0.05). Conclusion: The adjuvant therapy of Shenmai injection for ACS patients undergoing PCI can inhibit the inflammatory response of the body, improve the level of cardiac markers, improve the cardiac function, improve the prognosis of the disease, and improve the drug safety.
2020, Vol. 26 
冀公网安备13080202000677号